

LIDDS research activities in intratumoral immunotherapy are in line with leading oncology expert recommendations

The European Society for Medical Oncology (ESMO) sponsored paper provides recommendations on the harmonization of methodologies, definitions and data collection that supports LIDDS research into delivering intratumoral immunotherapies using NanoZolid® technology.

UPPSALA, SWEDEN – LIDDS AB (publ) research into the use of NanoZolid® technology for the intratumoral delivery of immunotherapy drugs stands to benefit from the ESMO expert panel guidance published in the scientific journal *Annals of Oncology*.

-The interest generated by this paper confirms that LIDDS' NanoZolid® technology has an important role to play in the dynamic and emerging field of intratumoral immunotherapy. We are very happy to see that our work matches the recommendations from the experts and their consensus and optimism for this treatment strategy, says Monica Wallter, CEO.

Immunotherapies use the body's own immune system to attack cancers. Immunoncology is one of the fastest growing areas of the pharmaceutical industry and the market is expected to grow to more than USD 100 billion by 2022.

LIDDS is actively working on several immune-oncology preclinical programs, including NanoZolid®-STING agonist formulations, focused on leveraging the potential of NanoZolid® to deliver treatments with long-lasting effects following injection into a range of different tumors, regardless of their location in the body.

A meeting focused exclusively on the intratumoral injection/administration of immunotherapies was held in March 2018 and the participants of the meeting were experts from academia and the pharmaceutical industry. The goal of the meeting was to provide a reference document endorsed by the panel members to provide guidance for clinical development of novel and efficacious intratumoral immunotherapies for the treatment of various cancers.

The conclusions of the meeting were published in *Annals of Oncology* and are available at: <https://doi.org/10.1093/annonc/mdy423>

For more information, please contact:

Monica Wallter, CEO, +46 (0)737 07 09 22, monica.wallter@liddspharma.com

LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in preclinical phase for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North (LIDDS). Redeye AB, Certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com.